Lightlake Therapeutics, Inc. (OTCQB: LLTP) is a biopharmaceutical company that develops treatments for common addictions and related disorders. Lightlake currently is developing an intranasal naloxone treatment to reverse opioid overdoses. The company has collaborated with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse of NIDA, part of the National Institute of Health, to develop this treatment. Lightlake also is focused on developing treatments in other areas, including for patients with Binge Eating Disorder, Bulimia Nervosa, and opioid drug addiction. For more information, visit the company’s website at www.lightlaketherapeutics.com